Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900198 · ClinicalTrials.gov registry record
Collection of Tissue Samples for Cancer Research
A clinical trial of Multiple Myeloma and Neoplasms, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 17
- Study locations
NCT00900198: Recruiting study of Multiple Myeloma and Neoplasms, sponsored by National Cancer Institute (NCI).
NCT00900198 is a study of Multiple Myeloma and Neoplasms that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 5,000 participants, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher). The trial reports 17 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900198, a study of Multiple Myeloma and Neoplasms, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 17
- Study locations
Study Summary
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure nece
Primary Outcome
Delinking of patient samples for research
Conditions Studied
Interventions
- PROCEDURE Biopsy
Study Locations (17)
Maryland
- Johns Hopkins University - Baltimore
- National Institutes of Health Clinical Center - Bethesda
California
- UC Davis - Sacramento
Colorado
- University of Colorado, Denver - Aurora
Georgia
- Emory University - Atlanta
Indiana
- Indiana University - Purdue - Indianapolis
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan Ann Arbor - Ann Arbor
Missouri
- Washington University - St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2006-07-06 |
What NCT00900198 shows while recruiting
NCT00900198 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Biopsy is the first listed.
NCT00900198 lists 17 locations in 16 states (Maryland, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00900198 about?
NCT00900198 is a clinical study titled "Collection of Tissue Samples for Cancer Research". Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for researc...
What is the current status of trial NCT00900198?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2006-07-06.
What conditions does trial NCT00900198 study?
This clinical trial studies the following conditions: Multiple Myeloma, Neoplasms, Myelodysplastic Syndrome, Lymphomas.
What interventions are being tested in trial NCT00900198?
The interventions under investigation include: Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00900198?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00900198 being conducted?
This trial has 17 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00900198's enrollment target sits among peer trials
5,000 5th of 438 higher than 432 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00991094 · 5,000 participants
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI